(NASDAQ)
1.74
+0.0400   (+2.35%)
After Hours: 1.75 +0.0100 (+0.57%)
Volume (24h) Market Cap. Day Range 52w Range
3.30M 198.03M 1.51 - 1.75 0.70 - 2.94
Mar-07-21 05:56AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)Newsfile
Mar-03-21 03:00AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)PR Newswire
Feb-22-21 01:46AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)Newsfile
Feb-20-21 07:00AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)ACCESSWIRE
Feb-18-21 09:47AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)PR Newswire
Feb-17-21 08:30AM AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery ProceduresPR Newswire
Feb-04-21 11:40AM When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Become Profitable?Simply Wall St.
Jan-26-21 10:04AM ROCE Insights For AcelRx PharmaceuticalsBenzinga
Jan-20-21 09:00AM AcelRx Announces Pricing of $27.5 Million Public Offering of Common StockPR Newswire
Jan-19-21 04:01AM AcelRx Announces Underwritten Public Offering of Common StockPR Newswire
08:30AM AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery RegimenPR Newswire
Jan-14-21 08:30AM AcelRx Announces Year-End 2020 Metrics and Review of 2020 AchievementsPR Newswire
Jan-13-21 10:30AM ROCE Insights For AcelRx PharmaceuticalsBenzinga
08:40AM Do Options Traders Know Something About AcelRx (ACRX) Stock We Don't?Zacks
Jan-12-21 11:39AM These 2 Penny Stocks Could Surge Over 300%, Say AnalystsTipRanks
Dec-10-20 09:00AM AcelRx Pharmaceuticals Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA®PR Newswire
08:30AM AcelRx Announces $10 Million Registered Direct Common Stock OfferingPR Newswire
Dec-09-20 12:20PM AcelRx Pharmaceuticals to Present at LD Micro Main EventPR Newswire
Dec-04-20 08:30AM AcelRx Pharmaceuticals Announces Partnership with the National Rural Health AssociationPR Newswire
Dec-02-20 10:58AM Is AcelRx Pharmaceuticals (ACRX) A Good Stock To Buy Now?Insider Monkey
Nov-18-20 08:30AM AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA®PR Newswire
Nov-07-20 07:08AM Analysts Are Upgrading AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) After Its Latest ResultsSimply Wall St.
Nov-06-20 01:28AM AcelRx Pharmaceuticals to Present at Credit Suisse 29th Annual Virtual Healthcare ConferencePR Newswire
Nov-05-20 08:20AM AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue EstimatesZacks
04:05AM AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial ResultsPR Newswire
Nov-05-20 02:30AM AcelRx Pharmaceuticals, Inc. to Host Earnings CallACCESSWIRE
Oct-29-20 04:05AM AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020PR Newswire
Oct-28-20 12:33PM AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks
Oct-21-20 10:46AM Aclaris (ACRS) Begins Phase II Study on Eczema CandidateZacks
Oct-15-20 10:26AM RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug DesignationZacks
Oct-13-20 12:00PM AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's WhyZacks
08:44AM AcelRx (ACRX) Looks Good: Stock Adds 5.3% in SessionZacks
Oct-12-20 08:59AM Is the Options Market Predicting a Spike in AcelRx (ACRX) Stock?Zacks
Sep-29-20 08:30AM AcelRx to Host Virtual KOL Event on Perioperative Use of DSUVIA®PR Newswire
Sep-23-20 06:48AM Reflecting on AcelRx Pharmaceuticals' (NASDAQ:ACRX) Share Price Returns Over The Last Three YearsSimply Wall St.
Sep-22-20 08:30AM AcelRx Awarded U.S. Army Contract for DSUVIA®PR Newswire
Sep-14-20 08:30AM AcelRx Announces DSUVIA® Added to the U.S. Department of Defense's Joint Deployment FormularyPR Newswire
Sep-10-20 04:05AM AcelRx Pharmaceuticals to Present at Two Upcoming ConferencesPR Newswire
Aug-31-20 05:00AM LD Micro - 360 Companies Set to Present this WeekACCESSWIRE
Aug-24-20 08:30AM AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Orthopedic Patients in the Perioperative SettingPR Newswire
Aug-19-20 08:30AM AcelRx Pharmaceuticals Announces Publication of Clinical Data on Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit (PACU) Following Preoperative Administration of DSUVIA®PR Newswire
Aug-11-20 12:00PM AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the UpgradeZacks
Aug-10-20 05:45AM AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue EstimatesZacks
04:01AM AcelRx Pharmaceuticals Reports Second Quarter 2020 Financial ResultsPR Newswire
Aug-03-20 04:05AM AcelRx to Host Second Quarter 2020 Financial Results Call and Webcast on Monday, August 10th, 2020PR Newswire
Jul-27-20 12:31PM Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q2 Earnings Expected to DeclineZacks
Jul-25-20 08:02AM New Forecasts: Here's What Analysts Think The Future Holds For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)Simply Wall St.
Jul-23-20 08:40AM AcelRx Announces Exclusive Distribution and Promotion Partnership for DSUVIA®PR Newswire
08:30AM AcelRx Announces $10 Million Common Stock Offering Priced At The MarketPR Newswire
Jun-22-20 10:11AM Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMTThomson Reuters StreetEvents
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Cap:    |  Volume (24h):